Phase 3 INSPIRE Study for EPP & XLP – Now Recruiting!
Participant recruitment is now underway for a phase 3 study of MT-7117, an investigational treatment for Erythropoietic Protoporphyria (EPP) and X-Linked Porphyria (XLP).
INSPIRE is a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
Fast Facts:
10 US sites open:
Boston, MA (2); Colombus, OH; Detroit, MI; Kansas City, KS; Los Angeles, CA; Miami, FL; New York, NY; Seattle, WA; and Winston-Salem, NC.
Site in California opening soon- please fill out an interest form to be matched to a site that is convenient to you.
Age 12+ with confirmed EPP/XLP diagnosis
Have not previously received dersimelagon
150 participants needed globally
The study drug is an oral medication
Study includes an optional open-label extension
Please click here to submit a confidential interest form.